Itraconazole Kent Pharma Uk

Itraconazole, the active ingredient in Itraconazole Kent Pharma Uk, is a triazole antifungal presented as an oral formulation for systemic use. It treats a range of fungal infections, including skin, nail and deep‑tissue mycoses, in adult patients as prescribed by a healthcare professional.

GNH USA supplies Itraconazole Kent Pharma Uk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Itraconazole is a triazole antifungal that interferes with fungal cell membrane synthesis across several disease families. - Dermatophytosis: effective in treating skin infections caused by dermatophyte fungi. - Onychomycosis: clears fungal infection of the nails, improving nail appearance and health. - Blastomycosis: used for systemic infection caused by Blastomyces dermatitidis. - Histoplasmosis: treats disseminated disease from Histoplasma capsulatum. - Coccidioidomycosis: manages infection by Coccidioides species. - Aspergillosis: employed in therapy of invasive disease caused by Aspergillus spp.

Adverse reactions may occur with itraconazole therapy and are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Vomiting: occasional episodes after dosing. - Abdominal pain: discomfort in the upper abdomen. - Headache: transient mild headache. - Rash: skin redness or itching. - Taste disturbances: altered taste perception.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Congestive heart failure: fluid retention and reduced cardiac function. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - QT prolongation: cardiac rhythm disturbances. - Anaphylaxis: rare severe allergic response.

Before initiating itraconazole, clinicians should consider several safety measures. - Liver function monitoring: assess baseline enzymes and repeat during therapy. - Cardiac assessment: avoid in patients with existing heart failure. - Drug interaction review: evaluate concurrent CYP3A4 substrates or inhibitors. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Hypersensitivity check: discontinue if allergic reaction occurs. - Store at ambient temperature: keep below 25°C in original container, protect from moisture and light.

Itraconazole has a notable interaction profile that requires careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may cause toxic levels. - Certain anti‑arrhythmics (e.g., quinidine): increase risk of cardiac arrhythmias. - Statins metabolized by CYP3A4 (e.g., simvastatin): heightened myopathy risk. - Oral contraceptives: reduced efficacy, risk of unintended pregnancy. - Doxorubicin: enhanced cardiotoxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower itraconazole exposure. - Warfarin: potential alteration of anticoagulant effect. - Phenytoin: may reduce antifungal concentrations. - Digoxin: possible increase in serum levels. - Antacids containing aluminum or magnesium: may decrease absorption.